91 related articles for article (PubMed ID: 7796410)
21. TabBO: a model reflecting common molecular features of androgen-independent prostate cancer.
Navone NM; Rodriquez-Vargas MC; Benedict WF; Troncoso P; McDonnell TJ; Zhou JH; Luthra R; Logothetis CJ
Clin Cancer Res; 2000 Mar; 6(3):1190-7. PubMed ID: 10741751
[TBL] [Abstract][Full Text] [Related]
22. Cotargeting tumor and stroma in a novel chimeric tumor model involving the growth of both human prostate cancer and bone stromal cells.
Hsieh CL; Gardner TA; Miao L; Balian G; Chung LW
Cancer Gene Ther; 2004 Feb; 11(2):148-55. PubMed ID: 14695756
[TBL] [Abstract][Full Text] [Related]
23. The dual impact of coxsackie and adenovirus receptor expression on human prostate cancer gene therapy.
Okegawa T; Li Y; Pong RC; Bergelson JM; Zhou J; Hsieh JT
Cancer Res; 2000 Sep; 60(18):5031-6. PubMed ID: 11016624
[TBL] [Abstract][Full Text] [Related]
24. Transfected neu oncogene induces human prostate cancer metastasis.
Zhau HY; Zhou J; Symmans WF; Chen BQ; Chang SM; Sikes RA; Chung LW
Prostate; 1996 Feb; 28(2):73-83. PubMed ID: 8604395
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor.
Eder IE; Hoffmann J; Rogatsch H; Schäfer G; Zopf D; Bartsch G; Klocker H
Cancer Gene Ther; 2002 Feb; 9(2):117-25. PubMed ID: 11857028
[TBL] [Abstract][Full Text] [Related]
26. Adenovirus-mediated delivery of human IFNgamma gene inhibits prostate cancer growth.
Zhao P; Zhu YH; Wu JX; Liu RY; Zhu XY; Xiao X; Li HL; Huang BJ; Xie FJ; Chen JM; Ke ML; Huang W
Life Sci; 2007 Aug; 81(9):695-701. PubMed ID: 17714738
[TBL] [Abstract][Full Text] [Related]
27. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis.
Matsubara S; Wada Y; Gardner TA; Egawa M; Park MS; Hsieh CL; Zhau HE; Kao C; Kamidono S; Gillenwater JY; Chung LW
Cancer Res; 2001 Aug; 61(16):6012-9. PubMed ID: 11507044
[TBL] [Abstract][Full Text] [Related]
28. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer.
Gotoh A; Ko SC; Shirakawa T; Cheon J; Kao C; Miyamoto T; Gardner TA; Ho LJ; Cleutjens CB; Trapman J; Graham FL; Chung LW
J Urol; 1998 Jul; 160(1):220-9. PubMed ID: 9628654
[TBL] [Abstract][Full Text] [Related]
29. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo.
Miyake H; Chi KN; Gleave ME
Clin Cancer Res; 2000 May; 6(5):1655-63. PubMed ID: 10815883
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of prostate tumor growth by overexpression of NudC, a microtubule motor-associated protein.
Lin SH; Nishino M; Luo W; Aumais JP; Galfione M; Kuang J; Yu-Lee LY
Oncogene; 2004 Apr; 23(14):2499-506. PubMed ID: 14676831
[TBL] [Abstract][Full Text] [Related]
31. Adenovirus-mediated Bax overexpression for the induction of therapeutic apoptosis in prostate cancer.
Li X; Marani M; Yu J; Nan B; Roth JA; Kagawa S; Fang B; Denner L; Marcelli M
Cancer Res; 2001 Jan; 61(1):186-91. PubMed ID: 11196158
[TBL] [Abstract][Full Text] [Related]
32. Delivery of the p53 tumor suppressor gene into lung cancer cells by an adenovirus/DNA complex.
Nguyen DM; Wiehle SA; Koch PE; Branch C; Yen N; Roth JA; Cristiano RJ
Cancer Gene Ther; 1997; 4(3):191-8. PubMed ID: 9171938
[TBL] [Abstract][Full Text] [Related]
33. Suppression of prostate tumor cell growth in vivo by WT1, the Wilms' tumor suppressor gene.
Fraizer G; Leahy R; Priyadarshini S; Graham K; Delacerda J; Diaz M
Int J Oncol; 2004 Mar; 24(3):461-71. PubMed ID: 14767530
[TBL] [Abstract][Full Text] [Related]
34. cis-Determinants in the cytoplasmic domain of CEACAM1 responsible for its tumor inhibitory function.
Izzi L; Turbide C; Houde C; Kunath T; Beauchemin N
Oncogene; 1999 Sep; 18(40):5563-72. PubMed ID: 10523833
[TBL] [Abstract][Full Text] [Related]
35. Targeting prostate cancer with conditionally replicative adenovirus using PSMA enhancer.
Lee SJ; Zhang Y; Lee SD; Jung C; Li X; Kim HS; Bae KH; Jeng MH; Kao C; Gardner T
Mol Ther; 2004 Dec; 10(6):1051-8. PubMed ID: 15564137
[TBL] [Abstract][Full Text] [Related]
36. Smad3 is overexpressed in advanced human prostate cancer and necessary for progressive growth of prostate cancer cells in nude mice.
Lu S; Lee J; Revelo M; Wang X; Lu S; Dong Z
Clin Cancer Res; 2007 Oct; 13(19):5692-702. PubMed ID: 17908958
[TBL] [Abstract][Full Text] [Related]
37. [Treatment of hepatocellular carcinoma with a novel gene-viral therapeutic system CNHK300-murine endostatin].
Li GC; Nie MM; Yang JM; Su CQ; Sun LC; Qian YZ; Sham J; Fang GE; Wu MC; Qian QJ
Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(11):943-8. PubMed ID: 15329284
[TBL] [Abstract][Full Text] [Related]
38. Prostate-specific expression of the diphtheria toxin A chain (DT-A): studies of inducibility and specificity of expression of prostate-specific antigen promoter-driven DT-A adenoviral-mediated gene transfer.
Li Y; McCadden J; Ferrer F; Kruszewski M; Carducci M; Simons J; Rodriguez R
Cancer Res; 2002 May; 62(9):2576-82. PubMed ID: 11980652
[TBL] [Abstract][Full Text] [Related]
39. Transcription-targeted gene therapy for androgen-independent prostate cancer.
Martiniello-Wilks R; Tsatralis T; Russell P; Brookes DE; Zandvliet D; Lockett LJ; Both GW; Molloy PL; Russell PJ
Cancer Gene Ther; 2002 May; 9(5):443-52. PubMed ID: 11961667
[TBL] [Abstract][Full Text] [Related]
40. Carboxyl-terminal repressor domain of MBP-1 is sufficient for regression of prostate tumor growth in nude mice.
Ghosh AK; Steele R; Ray RB
Cancer Res; 2005 Feb; 65(3):718-21. PubMed ID: 15705866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
